Gastrointestinal: Liver

Systemic Lupus Erythematosus

Volumn , Issue , 2011, Pages 865-886

  Mackay, Ian R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651372050     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374994-9.10046-4     Document Type: Chapter

References (181)

1. Cohen A.S., Reynolds W.E., Franklin E.C., Kulka J.P., Ropes M.W., Shulman L.E., et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971, 21:643-648.
2. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
3. Anonymous The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
4. Tan E.M. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44:93-151.
5. Temple L.K.F., McLeod R.S., Gallinger S., Wright V.G. Defining disease in the genomics era. Science 2001, 293:807-808.
6. Scadding J.G. Essentialism and nominalism in medicine: Logic of diagnosis in disease terminology. Lancet 1996, 348:594-596.
7. Mackay I.R. The prognoses of chronic hepatitis. Ann Intern Med 1972, 77:649-651.
8. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
9. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
10. Mackay I.R. Historical reflections on autoimmune hepatitis. World J Gastroenterol 2008, 14(21):3292-3300.
11. Barker M.H., Capps R.B., Allen F.W. Chronic hepatitis in the Mediterranean theatre. JAMA 1945, 129:653-659.
12. Wood I.J., King W.E., Parsons P.J., Perry J.W., Freeman M., Limbrick L. Non-suppurative hepatitis: A study of acute and chronic forms with special reference to biochemical and histological changes. Med J Aust 1948, 11:249-261.
13. Waldenstrom J. Leber, Blutproteine und Nahrungseiweiss. Dtsch. Gesellschaft Verdauungs-und Stoffwechselkrankheiten 1950, 15:113-119.
14. Kunkel H.G., Ahrens J.R., Eisenmenger W.J., Bongiovanni A.M., Slater R.J. Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology [abstract]. J Clin Invest 1951, 30:654.
15. Bearn A.G., Kunkel H.G., Slater R.J. The problem of chronic liver disease in young women. Am J Med 1956, 21:3-15.
16. Mackay I.R., Taft L.I., Cowling D.C. Lupoid hepatitis. Lancet 1956, 2:1323-1326.
17. Mackay I.R., Gajdusek D.C. An "autoimmune" reaction against human tissue antigens in certain acute and chronic diseases: II. Clinical correlations. Arch Intern Med 1958, 101:30-46.
18. Mackay I.R., Weiden.S., Hasker J. Autoimmune hepatitis. Ann N Y Acad Sci 1965, 124:767-780.
19. Bradbear R.A., Robinson W.N., Cooksley W.G.E., Halliday J.W., Harris O.D., Powell L.W. Are the causes and presentation of chronic hepatitis changing? An analysis of 104 cases over 15 years. Q J Med 1984, 53:279-288.
20. Parker D.R., Kingham I.G.C. Type 1 autoimmune hepatitis is primarily a disease of later life. Q J Med 1997, 90:289-296.
21. Krook H. Liver cirrhosis in patients with a lupus erythematosus-like syndrome. Acta Med Scand 1961, 169:713-726.
22. Read A.E., Sherlock S., Harrison C.V. Active "juvenile" cirrhosis as part of a systemic disease and the effect of corticosteroid therapy. Gut 1963, 4:378-393.
23. Reynolds T.B., Edmondson H.A., Peters R.L., Redeker A. Lupoid hepatitis. Ann Intern Med 1964, 61:650-666.
24. MacLachlan M.J., Rodnan G.P., Cooper W.M., Fennell R.H. Chronic active ("lupoid") hepatitis: A clinical, serological and pathological study of 20 patients. Ann Intern Med 1965, 62:425-462.
25. Miescher P.A., Braverman A., Amorosi E. Progressive hypergammaglobulinaemic hepatitis. Dtsch Med Wschr 1966, 91:1525-1532.
26. Soloway R.D., Summerskill D.M., Baggenstoss A.H., Shoenfield L.J. "Lupoid" hepatitis, a nonentity in the spectrum of chronic active liver disease. Gastroenterology 1975, 63:458-465.
27. Czaja A.J., Davis G.L., Ludwig J., Baggenstoss A.H., Taswell H.F. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983, 85:713-717.
28. Trimble R.B., Townes A.S., Robinson H., Kaplan S.B., Chandler R.W., Hanissian A.S., et al. Preliminary criteria for the classification of systemic lupus erythematosus (SLE). Evaluation in early diagnosed SLE and rheumatoid arthritis. Arthritis Rheum 1974, 17:184-188.
29. Leevy C.M., Popper H., Sherlock S. Diseases of the liver and biliary tract. Standardization of nomenclature, diagnostic criteria and diagnostic methodology. "Fogarty International Centre Proceedings No. 22," 1976, 76-725. U.S. Government Printing Office, Washington, DC, DHEW Publication No. (NIH).
30. Hodges J.R., Millward-Sadler G.H., Wright R. Chronic active hepatitis: The spectrum of disease. Lancet 1982, 1:550-552.
31. Mackay I.R. Autoimmune diseases of the liver. The Autoimmune Diseases 1985, 291-337. Academic Press, Orlando, FL. N.R. Rose, I.R. Mackay (Eds.).
32. International Hepatology Informatics Group Diseases of the liver and biliary tract. Standardisation of Nomenclature, Diagnostic Criteria and Prognosis 1994, Raven, New York. C.M. Leevy, S. Sherlock, N. Tygstrup, R. Zetterman (Eds.).
33. International Working Party Terminology of chronic hepatitis. Am J Gastroenterol 1995, 90:181-189.
34. Hennes E.M., Zeniya M., Czaja A.J., Parés A., Dalekos G.N., Krawitt E.L., et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48(1):169-176.
35. Pistina M., Wallace D.J., Nessim S., Metzger A.L., Klinenberg J.R. Lupus erythematosus in the 1980s: A survey of 570 patients. Semin Arthritis Rheum 1991, 21:55-64.
36. Schaffner F., Popper H. Non-specific reactive hepatitis in aged and infirm people. Am J Dig Dis 1959, 4:399.
37. Runyon B.A., LaBreque D.R., Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Am J Med 1980, 69:187-194.
38. Gibson T., Myers A.R. Subclinical liver disease in systemic lupus erythematosus. J Rheumatol 1981, 8:752-759.
39. Miller M.H., Urouitz M.B., Gladman D.D., Blendis L.M. The liver in systemic lupus erythematosus. Q J Med 1984, 53:401-409.
40. Van Steenbergen W., Beyls J., Vermylen J., Fevery J., Marchal G., Desmet V., et al. Lupus anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature. J Hepatol 1986, 3:87-94.
41. Leggett B.A. The liver in systemic lupus erythematosus. J Gastroenterol Hepatol 1993, 8:84-88.
42. Ruiz F.P., Martinez J.O., Mendoza A.C.Z., Del Arbol L.R., Caparros A.M. Nodular regenerative hyperplasia of the liver in rheumatic diseases: Report of seven cases and review of the literature. Semin Arthritis Rheum 1991, 21:47-54.
43. Sekiya M., Sekigawa I., Hishikawa T., Iida N., Hashimoto H., Hirose S. Nodular regenerative hyperplasia of the liver in systemic lupus erythematosus. Scand J Rheumatol 1997, 26:215-217.
44. Crapper R.M., Bhathal P.S., Mackay.I.R., Frazer I.H. "Acute" autoimmune hepatitis. Digestion 1986, 34:216-225.
45. Czaja A.J. Autoimmune chronic active hepatitis. Chronic Active Hepatitis. The Mayo Clinic Experience 1986, 105-126. Dekker, New York. A.J. Czaja, E.R. Dickson (Eds.).
46. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 1996, 334:897-903.
47. Golding P.L., Smith M., Williams R. Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med 1973, 55:772-782.
48. Rizzeto M., Swana G., Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973, 15:331-344.
49. Rizzeto M., Bianchi F.B., Doniach D. Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology 1974, 26:589-601.
50. Homberg J.C., Abuaf N., Bernard O., et al. Chronic active hepatitis with anti-liver/kidney microsome antibody type 1: A second type of autoimmune hepatitis. Hepatology 1987, 7:1333-1339.
51. Lindgren S., Braun H.-B., Michel G., Nemeth A., Nilsson S., Thome-Kromer B., et al. Absence of LKM antibody reactivity in autoimmune and hepatitis C-related chronic liver disease in Sweden. Scand J Gastroenterol 1997, 32:175-178.
52. Tanaka E., Kiyosawa K., Seki T., Matsumoto A., Sodeyama T., Furuta S., et al. Low prevalence of hepatitis C infection in patients with autoimmune hepatitis type 1. J Gastroenterol Hepatol 1993, 8:442-447.
53. Mackay I.R. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009 2009, 33(3-4):170-177.
54. Woodward J., Neuberger J. Autoimmune overlap syndromes. Hepatology 2001, 33:994-1002.
55. Rust C., Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008, 14(21):3368-3373.
56. Kenny R.P., Czaja A.J., Ludwig J., Dickson E.R. Frequency and significance of antimitochondrial antibodies in severe chronic hepatitis. Dig Dis Sci 1986, 31:705-711.
57. Chazouillères O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
58. Lohse A.W., Meyer zum Büschenfelde K.-H., Franz.B., et al. Characterization of the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999, 29:1078-1084.
59. Hall S., Axelsen P.H., Larson D.E., Bunch T.W. Systemic lupus erythematosus developing in patients with primary biliary cirrhosis. Ann Intern Med 1984, 100(3):388-389.
60. Mackay I.R., Whittingham S., Fida S., Myers M., Ikuno N., Gershwin M.E., et al. The peculiar immunity of primary biliary cirrhosis. Immunol Rev 2000, 174:226-237.
61. Powell F.C., Schroeter A.L., Dickson E.R. Primary biliary cirrhosis and the CREST syndrome: A report of 22 cases. Q J Med 1987, 62:75-82.
62. Mackay I.R., Rowley M.J., Whittingham S.F. Nuclear autoantibodies in primary biliary cirrhosis. Immunology and Liver: Falk Symposium Number 70, Immunology and Liver 1993, 397-409. Kluwer, Dordrecht. K.-H. Meyer zum Buschenfelde, J. Hoofnagle, M. Manns (Eds.).
63. Brünner G., Klinge O. A cholangitis with antinuclear antibodies (immuno-cholangitis) resembling chronic destructive non-suppurative cholangitis. Dtsch Med Wschr 1987, 112:1454-1458.
64. Goodman Z.D., McNally P.R., Davis D.R., Ishak K.G. Autoimmune cholangitis: A variant of primary biliary cirrhosis. Clinicopathologic and serologic correlation in 200 cases. Dig Dis Sci 1995, 40:1232-1242.
65. Kinoshita H., Omagari K., Matsuo I., et al. Autoimmune cholangitis: Serological features in 21 Japanese cases compared with those in primary biliary cirrhosis and autoimmune hepatitis. Liver 1999, 14:122-128.
66. Mackay I.R., Taft L.I., Cowling D.C. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet 1959, 1:65-69.
67. de Groote J., Desmet V.J., Gedigk P., et al. A classification of chronic hepatitis. Lancet 1968, 2:626-628.
68. International group of pathologists Acute and chronic hepatitis revisited. Lancet 1977, 2:914-919.
69. Page A.R., Good R.A. Plasma cell hepatitis with special attention to steroid therapy. J Dis Child 1960, 99:288-314.
70. Popper H., Paronetto F., Schaffner F. Immune processes in the pathogenesis of liver disease. Ann N Y Acad Sci 1965, 124:781-799.
71. Cooksley W.C.E., Bradbear R.A., Robinson W., Harrison H., Halliday J.W., Powell L.W., et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986, 6:345-348.
72. Searle J., Harmon B.V., Bishop C.S., Kerr J.F.R. The significance of cell death by apoptosis in hepatobiliary disease. J Gastroenterol Hepatol 1987, 2:77-96.
73. Czaja A.J., Nishioka M., Morshed S., Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994, 107:200-207.
74. Czaja A.J., Homburger H.A. Autoantibodies in liver disease. Gastroenterology 2001, 120(1):239-249.
75. Tan E.M., Feltkamp T.E.W., Smolen J.S., et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997, 40:1601-1611.
76. Vergani D., Alvarez F., Bianchi F.B., Cançado E.L., Mackay I.R., Manns M.P., et al. Liver autoimmune serology: A consensus statement from the Committee for Autoimmune Serology of the International Autoimmune Hepatitis Group. J Hepatol 2004, 41(4):677-683.
77. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: Current diagnostic and clinical challenges. World J Gastroenterol 2008, 14(21):3374-3387.
78. Mackay I.R. Antinuclear (chromatin) autoantibodies in autoimmune hepatitis. J Gastroenterol Hepatol 2001, 16:245-247.
79. Konikoff F., Swissa M., Schoenfeld Y. Autoantibodies to histones and their subfractions in chronic liver diseases. Clin Immunol Immunopathol 1989, 51:77-82.
80. Czaja A.J., Ming C., Shirai M., Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol 1995, 23:32-38.
81. Kenneally D., Mackay I.R., Toh B.H. Antinucleolar autoantibodies demonstrated by monolayers of human fibroblasts in sera from patients with systemic lupus erythematosus, progressive systemic sclerosis and chronic active hepatitis. J Clin Lab Immunol 1984, 14:13-16.
82. Wesierska-Gadek J., Penner E. Nuclear antigens. Molecular Basis of Autoimmune Hepatitis 1996, 23-44. Landes, Austin, TX. I.G. McFarlane, R. Williams (Eds.).
83. Jain S., Markham T., Thomas H.C. Double stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol 1976, 26:35-41.
84. Peretz A., Mascart-Lemone F., Nuttin G., Famaey J.P. Chronic active hepatitis with a high level of anti-ds-DNA detected by a solid phase radioimmunoassay. Clin Rheumatol 1982, 1:208-211.
85. Smeenk R., van der Lelij G., Swaak T. Specificity in systemic lupus erythematosus of antibodies to double-stranded DNA measured with the polyethylene glycol precipitation assay. Arthritis Rheum 1982, 25:631-638.
86. Leggett B.A., Collins R.V., Cooksley W.G.E., Prentice D.I., Powell L.W. Evaluation of the Crithidia assay to distinguish between chronic active hepatitis and systemic lupus erythematosus. J Gastroenterol Hepatol 1987, 2:202-211.
87. Emlen W., O'Neill L. Clinical significance of antinuclear antibodies. Comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997, 40:1612-1618.
88. Konikoff F., Schoenfeld Y., Isenberg D.A., Barrison I., Sobe T., Theodor E., et al. Anti-Rnp antibodies in chronic liver diseases. Clin Exp Rheumatol 1987, 5:359-361.
89. Penner E., Kindas-Mugge I., Hitchman E., Sauermann G. Nuclear antigens recognized by autoantibodies present in liver disease sera. Clin Exp Immunol 1986, 63:428-433.
90. Nishioka M., Morshed S.A., Parveen S., Ming C. Heterogeneity of antinuclear antibodies in autoimmune liver diseases. Autoimmune Liver Diseases 1998, 179-216. Elsevier, Amsterdam. second ed. E.L. Krawitt, R.H. Wiesner, M. Nishioka (Eds.).
91. Elkon K., Skelly S., Parnassa A., Moller A.P., Danho W., Weissbach H., et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci USA 1986, 83:7419-7423.
92. Lin J.L., Dubljevic V., Fritzler M.J., Toh B.H. Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: Application to a novel ELISA for systemic lupus erythematosus. Clin Exp Immunol 2005, 141(1):155-164.
93. Koren E., Schnitz W., Reichlin M. Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum 1993, 36:1325-1328.
94. Koren E., Reichlin M.W., Koscec M., Fugate R.D., Reichlin M. Autoantibodies to the ribosomal P proteins react with a plasma membrane related target on human cells. J Clin Invest 1992, 89:1236-1241.
95. Koscec M., Koren E., Wolfson-Reichlin M., Fugate R.D., Trieu E., Targoff I.N., et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997, 159:2033-2041.
96. Arnett F.C., Reichlin M. Lupus hepatitis: An under-recognized feature associated with autoantibodies to ribosomal P. Am J Med 1995, 99:465-472.
97. Hulsey M., Coldstein R., Scully L., Surbeck W., Reichlin M. Anti-ribosomal P antibodies in systemic lupus erythematosus: A case control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995, 74:252-256.
98. Ohira H., Takiguchi J., Rai T., Abe K., Yokokawa J., Sato Y., et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res 2004, 28(3):137-139.
99. Wesierska-Gadek J., Penner E., Hitchman E., Sauermann G. Antibodies to nuclear lamins in autoimmune liver disease. Clin Immunol Immunopathol 1988, 49:107-115.
100. Smalley M.J., Mackay I.R., Whittingham S. Antinuclear factors and human leucocytes: Reaction with granulocytes and lymphocytes. Aust Ann Med 1968, 17:28-32.
101. Zauli D., Ghetti S., Grassi A., Descovich C., Cassam F., Ballardini G., et al. Neutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Hepatology 1997, 25:1005-1007.
102. Spronk P.E., Bootsma H., Horst G., Huitema M.G., Limburg P.C., Cohen Tervaert J.W., et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996, 35:625-631.
103. Mackay I.R., Toh B.-H. Autoimmune hepatitis. The way we were, the way we are today, and the way we hope to be. Autoimmunity 2002, 35:293-305.
104. Berg P.A., Stechemesser E., Strienz J., et al. Hypergammaglobulinämische chronisch aktive Hepatitis mit Nachweis von leber-pankreas-spezifischen komplemtbindenden Antikörpen. Verh Dtsch Ges Inn Med 1981, 87:921-927.
105. Manns M., Gerken G., Kyriatsoulis A., et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987, 1:292-294.
106. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
107. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP (ser) sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 2000, 121:364-374.
108. Kevenbeck T., Lohse A.W., Grötzinger J.A. A conformational approach suggests the function of the autoimmune hepatitis target antigen soluble liver antigen/liver pancreas. Hepatology 2001, 34:230-233.
109. Herkel J., Manns M.P., Lohse A.W. Selenocystine, soluble liver antigen/liver-pancreas, and autoimmune hepatitis. Hepatology 2007, 46:275-277.
110. Manns M.P., Obermayer-Straub P. Cytochromes P450 and UDP-glucuronyl transferases: Model antigens to study drug-induced, virus-induced and autoimmune liver disease. Hepatology 1997, 26:1054-1066.
111. Waxman D.J., Lapenson D.P., Krishnan M., Bernard O., Kreibich G., Alvarez F. Antibodies to liver/kidney microsomes in chronic active hepatitis recognize specific forms of hepatic cytochrome P450. Gastroenterology 1988, 95:1326-1331.
112. Manns M.P., Johnson E.F., Griffin K.J., Tan E.M., Sullivan K.F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db. J Clin Invest 1989, 83:1066-1072.
113. Manns M.P., Griffin K.J., Sullivan K.F., Johnson E.F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P450 monooxygenase. J Clin Invest 1991, 88:1370-1378.
114. Homberg J.-C., André C., Abuaf N. A new anti-liver/kidney microsome antibody (anti-LKM2) in tienilic induced hepatitis. Clin Exp Immunol 1984, 55:561-570.
115. Beaune P.H., Dansette P.M., Mansuy D., Kiffel L., Finck M., Amar C., et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis directed against a human liver cytochrome P450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987, 84:551-555.
116. Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., et al. Anti-liver endoplasmatic reticulum auto-antibodies are directed against human cytochrome P450 IA2: A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990, 85:1967-1973.
117. Crivelli O., Lavarini C., Chiaberge E.A., Amoroso A., Farci P., Negro F., et al. Microsomal auto-antibodies in chronic infection with the HBsAg associated delta (δ) agent. Clin Exp Immunol 1983, 54:232-238.
118. Durazzo M., Philipp T., van Pelt F.N.A.M., Lüttig B., Borghesio E., Michel G., et al. Heterogeneity of microsomal auto-antibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology 1995, 108:455-462.
119. Strassburg C.P., Obermayer-Straub P., Alex B., Durazzo M., Rizzetto M., Tukey R.H., et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996, 111:1582-1592.
120. Bachrich T., Thalhammer T., Jäger W., Haslmayer P., Alihodzic B., Bakos S., et al. Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology 2001, 33:1053-1059.
121. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2006, 91:2843-2850.
122. Peterson P., Uibo R., Kampe O. Polyendocrine syndromes. The Autoimmune Diseases 2006, 515-526. Academic Press, San Diego. fourth ed. N.R. Rose, I.R. Mackay (Eds.).
123. De Voss J.J., Shum A.K., Johannes K.P., Lu W., Krawisz A.K., Wang P., et al. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol 2008, 181(6):4072-4079.
124. McMurray R.W., Elbourne K. Hepatitis C virus infection and autoimmunity. Semin. Arthritis Rheum 1997, 26:689-701.
125. Clifford B.D., Donahue D., Sonith L., Cable E., Lüttig B., Manns M., et al. Prevalence of serological markers of autoimmunity in patients with hepatitis C. Hepatology 1995, 21:613-619.
126. Lunel F., Abauf N., Frangeul L., et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992, 16:630-636.
127. Choudhuri K., Miele-Vergani G., Vergani D. Cytochrome P4502D6: Understanding an autoantigen. Clin Exp Immunol 1997, 108:381-383.
128. Vidali M., Hildestrand E., Eliasson E., Motteran E., Reale R., Rolla G., et al. Use of molecular stimulation for mapping conformational CYP2E1 epitopes. J Biol Chem 2004, 279:50949-50955.
129. Kammer A.R., Van der Burg S.H., Grabscheid B., Hunziger I.P., Kwappenberg K.M., Reichen J., et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999, 190:169-176.
130. Martin E., Abauf N., Cavalli F., Durand V., Johanet C., Homberg J-C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988, 8:1662-1666.
131. Abauf N., Johanet C., Chretien P., Martini E., Soulier E., Laperche S., et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992, 16:892-898.
132. Han S., Tredger M., Gregorio G.V., Mieli-Vergani G., Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995, 21:58-62.
133. Muratori L., Cataleta M., Muratori P., Manotti P., Lenzi M., Cassani F., et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: Comparison of different techniques. J Immunol Methods 1995, 187:259-264.
134. Lapierre P., Hajoui O., Homberg J.-C., Alvarez F. Formaminotransferase cyclodeaminase is an organ-specific autoantigen recognised by sera of patients with autoimmune hepatitis. Gastroenterology 1999, 116:643-649.
135. Lapierre P., Johanet C., Alvarez F. Characterization of the B cell response of patients with anti-liver cytosol autoantibodies in type 2 autoimmune hepatitis. Eur J Immunol 2003, 33(7):1869-1878.
136. Toh B.-H. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol 1979, 38:621-628.
137. Whittingham S., Irwin J., Mackay I.R., Smalley M. Smooth muscle autoantibody in "autoimmune" hepatitis. Gastroenterology 1966, 51:499-505.
138. Fusconi M., Cassani F., Lenzi M., Ballardini G., Volta U., Bianchi F.B. Anti-actin antibodies: A new test for an old problem. J Immunol Methods 1990, 130:1-8.
139. Cancado E.L.R., Abrantes-Lemos C.P., Vilas-Boas L.S., Novo N.F., Carrilho F.J., Laudanna A.A. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Autoimmun 2001, 17:223-228.
140. Chhabra D., dos Remedios C.G. Actin: An overview of its structure and function. Actin, Actin-Binding Proteins and Disease 2008, 50-64. Springer, New York. C. dos Remedios, D. Chhabra (Eds.).
141. Whittingham S., Mackay I.R., Irwin J. Autoimmune hepatitis. Immunofluorescence reactions with cytoplasm of smooth muscle and renal glomerular cells. Lancet 1966, 1(7451):1333-1335.
142. Lidman K., Biberfeld G., Fagraeus A., Norberg R., Torstensson R., Utter G., et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976, 24(2):266-272.
143. Silvestrini R.A., Benson E.M. Whither smooth muscle antibodies in the third millennium. J Clin Pathol 2001, 54:677-678.
144. Mackay I.R., Czaja A.J., McFarlane I.G., Manns M.P. Chronic hepatitis. The Autoimmune Diseases 2006, 729-747. Academic Press, San Diego. fourth ed. N.R. Rose, I.R. Mackay (Eds.).
145. Mackay I.R., Martinez-Neira R., Whittingham S., Nicolay D., Toh B.-H. Autoantigenicity of actin. Actin, Actin-Binding Proteins and Disease 2008, 50-64. Springer, New York. C. dos Remedios, D. Chhabra (Eds.).
146. Yasuura S., Veno T., Watanabe S., Hirose M., Namahisa T. Immunocytochemical localization of myosin in normal and phalloidin-treated rat hepatocytes. Gastroenterology 1989, 97:982-989.
147. Watanabe S., Miyazaki A., Hirose M., Takeuchi M., Ohide H., Kitamura T., et al. Myosin in hepatocytes is essential for bile canalicular contraction. Liver 1991, 11(3):185-189.
148. Czaja A.J., Cassani F., Cataleta M., Valentine P., Bianchi F.B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996, 24:1068-1073.
149. McFarlane I.G., McFarlane B.M., Major G.N., Tolley P., Williams R. Identification of the hepatic asialoglycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP). Clin Exp Immunol 1984, 55:347-354.
150. McFarlane B. Hepatocellular membrane antigens. Molecular Basis of Autoimmune Hepatitis 1996, 75-104. Landes, Austin, TX. I.G. McFarlane, R. Williams (Eds.).
151. Treichel U., McFarlane B., Seki T., et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994, 107:799-804.
152. Schreiter T., Liu C., Gerken G., Treichel U. Detection of circulating autoantibodies directed against the asialoglycoprotein receptor using recombinant receptor subunit H1. J Immunol Methods 2005, 301(1-2):1-10.
153. Matsuo I., Ikuno N., Omagari K., Kinoshita H., Oka M., Yamaguchi H., et al. Autoimmune reactivity of sera to hepatocyte plasma membrane in type 1 autoimmune hepatitis. J Gastroenterol 2000, 35:226-234.
154. Tahiri F., Le Naour F., Huguet S., Lai-Kuen R., Samuel D., Johanet C., et al. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology 2008, 47(3):937-948.
155. Ma Y., Bogdanos D.P., Hussain M.J., Underhill J., Bansal S., Longhi M.S., et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006, 130(3):868-882.
156. Longhi M.S., Hussain M.J., Bogdanos D.P., Quaglia A., Mieli-Vergani G., Ma Y., et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46(2):472-484.
157. Fairhurst A.M., Wandstrat A.E., Wakeland E.K. Systemic lupus erythematosus: Multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006, 92:1-69.
158. Wakeland E.K., Liu K., Graham R.R., Behrens T.W. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001, 15:397-408.
159. Jacob C.O., Zhu J., Armstrong D.L., Yan M., Han J., Zhou X.J., et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009, 106(15):6256-6261.
160. McCombe P.A., Greer J.M., Mackay I.R. Sexual dimorphism in autoimmune disease. Curr Mol Med 2009, 9:1058-1079.
161. Rowley M.J., Mackay I.R. Measurement of antibody-producing capacity in man. I. The normal response to flagellin from Salmonella adelaide. Clin Exp Immunol 1969, 5:407-418.
162. Mackay I.R., Morris P.J. Association of autoimmune chronic hepatitis with HLA-A1-B8. Lancet 1972, 2:793-795.
163. Mackay I.R., Tait B.D. HLA associations with autoimmune-type chronic active hepatitis: Identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980, 79:95-98.
164. Mackay I.R., O'Brien.R.M., Whittingham S., Tait B.D. Immunogenetic aspects. Autoimmune hepatitis and other diseases of the liver 1991, Vol. 2:119-213. CRC Press, Boca Raton, FL. N. Farid (Ed.).
165. Tait B., Mackay I.R., Board P.H., Coggan M., Emery P., Eckardt G. HLA A1, B8, DR3 extended haplotypes in autoimmune chronic hepatitis. Gastroenterology 1989, 97:479-481.
166. Doherty D.G., Underhill J.A., Donaldson P.T., Manabe K., Mieli-Vergani G., Eddleston A.L.F.W., et al. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 1994, 18:243-249.
167. Donaldson P.T., Doherty D.G., Hayllar K.M., McFarlane I.G., Johnson P.J., Williams R. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991, 13:701-706.
168. Czaja A.J., Strettell M.D., Thomson L.J., Santrachi P.J., Moore S.B., Donaldson P.T., et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997, 25:317-323.
169. Doherty D.G., Donaldson P.T., Underhill J.A., et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994, 19:609-615.
170. Czaja A.J., Donaldson P.T. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol. Rev 2000, 174:250-259.
171. Vergani D., Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008, 14:3306-3312.
172. Djilali-Saiah I., Ouellette P., Caillat-Zucman S., Debray D., Kohn J.I., Alvarez F. CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 2001, 62(12):1356-1362.
173. Chang S., Yang L., Moon Y.M., Cho Y.G., Min S.Y., Kim T.J., et al. Anti-nuclear antibody reactivity in lupus may be partly hard-wired into the primary B-cell repertoire. Mol Immunol 2009, 46(16):3420-3426.
174. Wick G., Hála K., Wolf H., Ziemiecki A., Sundick R.S., Stöffler-Meilicke M., et al. The role of genetically-determined primary alterations of the target organ in the development of spontaneous autoimmune thyroiditis in obese strain (OS) chickens. Immunol Rev 1986, 94:113-136.
175. Molecular mimicry. Cell Mol Life Sci 2000, 57:523-578. Multiauthor Review (J.M. Davies, Coordinator).
176. Vento S., Guella L., Mirandola F., Cainelli F., Di Perri G., Solbiati M., et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995, 346:608-609.
177. Béland K., Lapierre P., Marceau G., Alvarez F. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun 2004, 22(2):159-166.
178. Vitozzi S., Lapierre P., Djilali-Saiah I., Marceau G., Beland K., Alvarez F. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection. Autoimmunity 2004, 37(3):217-222.
179. Mackay I.R. Immune mechanisms and liver toxicity. Handbook of Experimental Pharmacology Series: Drug-Induced Hepatotoxicity 1996, 221-247. Springer, Berlin. R.G. Cameron, G. Feuer, F.A. de la Inglesia (Eds.).
180. Biburger M., Tiegs G. Animal models of autoimmune liver disease. Liver Immunology. Principles and Practice 2007, 293-308. Humana Press, Totowa, NJ. second ed. M.E. Gershwin, J.M. Vierling, M.P. Manns (Eds.).
181. Lapierre P., Djilali-Saiah I., Vitozzi S., Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 39 (4) 2004, 1066-1074.